Johnson & Johnson Says Phase 3B Data for Tremfya in Psoriatic Arthritis Continued to Show Reduction in Symptoms
Published on 11/17/2025 at 10:23 pm IST

|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 218.82 USD | +0.13% |
|
+6.45% | +5.83% |
| 11:42pm | Ex-CEO sued by New York for insider trading tied to COVID-19 vaccine contamination | RE |
| 11:37pm | N.Y. Attorney General Sues Former Emergent Biosolutions CEO for Insider Trading -- Update | DJ |
Published on 11/17/2025 at 10:23 pm IST

Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.

Select your edition
All financial news and data tailored to specific country editions